A Review of MicroRNAs Related to the Occurrence, Diagnosis, and Prognosis of Non-small Cell Lung Cancer

Jun Wang\textsuperscript{a}, Li Ke\textsuperscript{a*}, Xian-liang Jiang\textsuperscript{a}, Can Zhang\textsuperscript{a}

\textsuperscript{a}Department of Chest Surgery, Anhui Provincial Hospital, Hefei 230001, Anhui, China.

Abstract

Non-small cell lung cancer (NSCLC) is the main most common type of lung cancer, accounting for about 80% of all cases. The five-year survival rate of patients with NSCLC is usually less than 20%. MicroRNAs (miRNAs), a type of small non-coding RNA, are closely related to the development and occurrence of tumors, including NSCLC. Here, we reviewed the miRNAs related to the occurrence, diagnosis and prognosis of NSCLC.

Keywords: miRNA; non-small cell lung cancer; occurrence; diagnosis; prognosis

MIRNAS IN THE OCCURRENCE AND DEVELOPMENT OF NSCLC

Lung cancer is a malignant tumor with the highest morbidity and mortality rates in the world. According to the International Agency for Research on Cancer \cite{1}, 1.82 million new cases of lung cancer were diagnosed worldwide in 2012, ranking first among all malignant tumors; the incidence and mortality rates of lung cancer in China are similarly alarming \cite{23}. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80% of all lung cancers \cite{4}. NSCLC is mainly divided into squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell lung cancer, and sarcomatoid carcinoma. Due to the lack of obvious clinical manifestations in its early stages, NSCLC is typically discovered late in the disease process; as a result, the prognosis of NSCLC is poor, and the five-year survival rate is usually less than 20% \cite{5}. Therefore, studying the mechanism of NSCLC occurrence and development is crucial for the diagnosis and treatment of NSCLC.

MicroRNA (miRNA) is a type of small molecule non-coding RNA with a length of about 18—25 base pairs, which regulate gene expression after transcription. It has been reported that miRNAs are abnormally expressed in a variety of tumors, and the dysregulated miRNAs may serve as tumor promoters or inhibitors \cite{6}. MiRNAs can regulate cell proliferation, differentiation and apoptosis through complete or incomplete matching with the target gene mRNA 3’UTR; thus they play an important role in the development of tumors and in tumor therapy research \cite{7}. Studies have shown that miRNAs have specific expression profiles in NSCLC, and serve as oncogenes or tumor-suppressor genes to promote or inhibit NSCLC cell proliferation, migration, and invasion \cite{8}. In addition, miRNAs can be used for the early detection, prognosis, radio-sensitivity and chemo-sensitivity prediction of NSCLC \cite{9}.

In this review, we summarized the miRNAs associated with carcinogenesis and cancer suppression in NSCLC and emphasized miRNAs’ potential as biomarkers for clinical diagnosis, prognosis and treatment.

MiRNAs as oncogenes in NSCLC

It has been demonstrated that miR-221 is aberrantly up-regulated in NSCLC tissues and NSCLC cells compared to normal tissues and cells, and has an oncogenic role by directly targeting TIMP2 \cite{12}. MiR-1285-5p promotes the proliferation, migration and invasion of NSCLC cells via down-regulating the two genes, Smad4 and CDH1 \cite{13}. In addition, Wang et al. \cite{14} discovered that miR-661 could target RUNX3 and serve as an oncogene in NSCLC. Liu et al. \cite{15} also revealed that miR-...
661 was up-regulated in NSCLC tissues compared with the paired adjacent tissues, and miR-661 promoted tumor invasion and metastasis by directly inhibiting RB1 in NSCLC. Huang et al. showed that miR-10b expression levels were higher in NSCLC tissues compared with an adjacent normal tissue control, and it could promote cancer cell growth by accelerating NSCLC’s cell cycle progression in the G0/G1 phase and suppressing cell apoptosis. Apaf-1 is associated with the suppression of apoptosis. In NSCLC cells, miR-484 accelerates the cell progression by inhibiting Apaf-1 expression. MiR-19 can enhance proliferation and inhibit apoptosis via the EGFR signaling pathway by targeting PP2A and BIM in NSCLC. In addition, Zeng et al. demonstrated that miR-205 promoted NSCLC cell growth in vitro and in vivo, which was related to Smad4. Sun et al. reported that miR-346 contributed to NSCLC growth and invasion in vitro and in vivo by regulating the XPC/ERK/Snail/E-cadherin pathway. MiR-1297 functions as a tumor promoter in NSCLC cells by targeting the PTEN/Akt/Skp2 signaling pathway. MiR-106a also promotes the growth and metastasis of NSCLC by targeting PTEN.

miR-145-3p inhibits cell growth, motility, and chemotaxis in NSCLC through suppression of the mTOR pathway by targeting PDK1. Zhou et al. revealed that miR-135a promoted cell apoptosis and inhibited cell proliferation, migration, invasion and tumor angiogenesis by targeting the IGF-1 gene through the IGF-1/PI3K/Akt signaling pathway in NSCLC. Jiang et al. showed that miR-1258 could inhibit NSCLC cell proliferation and induced senescence and apoptosis via targeting the GRB2/Ras/Erk pathway. Furthermore, miR-542-3p exerts tumor suppressive functions in NSCLC by down-regulating FTSJ2. MiR-509-5p decreases cell proliferation, migration, and the invasive capability of NSCLC cells by negatively regulating FOXM1 expression. MiR-194 also suppresses tumor growth through function as a negative regulator of CUL4B in ESCC.

### Table 1 The oncogenic miRNAs in NSCLC

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Biological mechanisms</th>
<th>Target genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-221</td>
<td>promotes cell proliferation, cell cycle, migration and invasion</td>
<td>TIMP2</td>
</tr>
<tr>
<td>miR-1285-5p</td>
<td>promotes cell proliferation, migration and invasion</td>
<td>CDH1 and Smad4</td>
</tr>
<tr>
<td>miR-661</td>
<td>promotes cell proliferation and invasion</td>
<td>RUNX3, RB1</td>
</tr>
<tr>
<td>miR-10b</td>
<td>promotes cancer cell growth by accelerating cell cycle progression in the G0/G1 phase and suppresses cell apoptosis</td>
<td>Klotho</td>
</tr>
<tr>
<td>miR-484</td>
<td>inhibits cell apoptosis</td>
<td>Apaf-1</td>
</tr>
<tr>
<td>miR-19</td>
<td>promotes cell proliferation and inhibits cell apoptosis</td>
<td>PP2A and BIM</td>
</tr>
<tr>
<td>miR-205</td>
<td>promotes tumor growth</td>
<td>Smad4</td>
</tr>
<tr>
<td>miR-346</td>
<td>contributes to cell growth and invasion</td>
<td>XPC/ERK/Snail/E-cadherin pathway</td>
</tr>
<tr>
<td>miR-1297</td>
<td>promotes cell proliferation</td>
<td>PTEN/Akt/Skp2 signaling pathway</td>
</tr>
<tr>
<td>miR-106a</td>
<td>promotes tumor growth and metastasis</td>
<td>PTEN</td>
</tr>
</tbody>
</table>

In addition, Zhang et al. reported that the low expression of miR-770 was correlated with poor patient survival in NSCLC, while miR-770 overexpression was capable of inhibiting NSCLC tumor growth by down-regulating JMJ16 and its downstream WNT/β-catenin pathway both in vitro and in vivo. Chen et al. demonstrated that the mTOR signaling pathway was dysregulated in more than 50% of all human malignancies and was a major target in cancer treatment, miR-145-3p inhibits cell growth, motility, and chemotaxis in NSCLC through suppression of the mTOR pathway by targeting PDK1. Zhou et al. revealed that miR-135a promoted cell apoptosis and inhibited cell proliferation, migration, invasion and tumor angiogenesis by targeting the IGF-1 gene through the IGF-1/PI3K/Akt signaling pathway in NSCLC. Jiang et al. showed that miR-1258 could inhibit NSCLC cell proliferation and induced senescence and apoptosis via targeting the GRB2/Ras/Erk pathway. Furthermore, miR-542-3p exerts tumor suppressive functions in NSCLC by down-regulating FTSJ2. MiR-509-5p decreases cell proliferation, migration, and the invasive capability of NSCLC cells by negatively regulating FOXM1 expression. MiR-194 also suppresses tumor growth through function as a negative regulator of CUL4B in ESCC.
Glycolysis has been considered a feature of cancer cells; Akt is a key enzyme in the regulation of glycolysis and energy metabolism in cancer cells. It has been determined that miR-124 is able to inhibit proliferation, glycolysis, and energy metabolism by targeting AKT-GLUT1/HKII in NSCLC cells [35]. VEGFs are important mediators of angiogenesis and lymphangiogenesis during tumor development [36]. MiR-128 can suppress tumorigenesis, angiogenesis and lymphangiogenesis in ESCC through down-regulating VEGF-C [37]. The aforementioned tumor-suppressor miRNAs and their targets in NSCLC are summarized in Table 2. According to these studies, when miRNA expression is significantly reduced in NSCLC, it can regulate the growth of tumors by inhibiting the related oncogenes and tumor factors. However, the relationship between miRNAs and NSCLC, especially the delicate mechanism of gene expression regulation of miRNAs, is still unclear. Studies on these issues should gradually clarify the mechanism of the occurrence and development of NSCLC and may also provide new methods for the early diagnosis and treatment of NSCLC.

**CLINICAL APPLICATIONS OF miRNAs IN NSCLC**

**Diagnostic value of miRNAs in NSCLC**

At present, the sensitivity and specificity of serum tumor markers are relatively low in the clinical diagnosis of patients with NSCLC, especially in the early stage of NSCLC. It is easy to misdiagnose or miss a diagnosis, delaying the optimum time for treatment. Profiling research has revealed the potential value of miRNAs for the early detection and screening of NSCLC. For example, Świtlik et al. [38] showed that miR-30a-5p and miR-210-3p could be used to discriminate NSCLC tissue from non-cancerous lung tissues. Geng et al. [39] reported that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) could be used as potential biomarkers in early screening for NSCLC. Zhu et al. [40] validated that the serum levels of three miRNAs (miR-182, miR-183, and miR-210) were significantly up-regulated and the miR-126 level was markedly down-regulated in NSCLC patients, which could serve as tumor biomarkers for early diagnosis of NSCLC. Moreover, miRNAs can also function as biomarkers for the classification of NSCLC. For example, Jin et al. [41] demonstrated that miR-181-5p, miR-30a-3p, miR-30e-3p, and miR-361-5p were adenocarcinoma-specific, while miR-10b-5p, miR-15b-5p, and miR-320b were SCC-specific. Molina-Pin elo et al. [42] showed that nine miRNAs were differentially expressed in SCC versus adenocarcinoma samples. Of these, six miRNAs (miR-205, miR-149, miR-422a, miR-708, miR-378, and miR-375) were validated. Furthermore, circulating miRNAs are also promising biomarkers for cancer detection. In NSCLC, a multicentric case-control study revealed that a five-miRNA panel, including miR-483-5p, miR-193a-3p, miR-25, miR-214, and miR-7 could serve as a potential biomarker for diagnosing NSCLC in patients of different races, even in the early stages of cancer. Of the five miRNAs, miR-483-5p, miR-193a-3p, and miR-25 are tumor cell growth/cycle-related miRNAs. MiR-7 is a tissue-specific miRNA, and miR-214 may be categorized as an immune response-related miRNA [43]. Giallombardo et al. [44] showed that eight plasma exosomal miRNAs, (miR-30b, miR-30c, miR-103, miR-122, miR-183, miR-193a-3p, miR-214, and miR-7) could serve as potential biomarkers in early screening for NSCLC.

---

**Table 2: The tumor-suppressor miRNAs in NSCLC**

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Biological mechanisms</th>
<th>Target genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-376a</td>
<td>inhibits cell proliferation and invasion, increases cell apoptosis</td>
<td>c-Myc</td>
</tr>
<tr>
<td>miR-183</td>
<td>inhibits cell proliferation, migration, invasion and tumor growth in nude mice</td>
<td>MTA1</td>
</tr>
<tr>
<td>miR-142-3p</td>
<td>inhibits cell proliferation and induces cell apoptosis</td>
<td>HMG1B</td>
</tr>
<tr>
<td>miRNA-204</td>
<td>suppresses cell proliferation and migration, induces apoptosis and G1 arrest</td>
<td>JAK2, ATF2</td>
</tr>
<tr>
<td>miR-770</td>
<td>inhibits NSCLC tumor growth</td>
<td>JMJ16</td>
</tr>
<tr>
<td>miR-145-3p</td>
<td>inhibits cell growth, motility and chemotaxis</td>
<td>PKD1</td>
</tr>
<tr>
<td>miR-135a</td>
<td>promotes cell apoptosis and inhibits cell proliferation, migration, invasion and tumor angiogenesis</td>
<td>IGF-1</td>
</tr>
<tr>
<td>miR-1258</td>
<td>inhibits cell proliferation, induces senescence and apoptosis</td>
<td>GRB2/Ras/Erk pathway</td>
</tr>
<tr>
<td>miR-542-3p</td>
<td>inhibits cell proliferation, migration, cell cycle, and tumor growth, induces cell apoptosis</td>
<td>FT3J2</td>
</tr>
<tr>
<td>miR-509-5p</td>
<td>decreases cell proliferation, migration and invasion</td>
<td>FOXM1</td>
</tr>
<tr>
<td>miR-194</td>
<td>suppresses cell proliferation and migration, and tumor growth</td>
<td>CUL4B</td>
</tr>
<tr>
<td>miR-124</td>
<td>inhibits proliferation, glycolysis, and energy metabolism</td>
<td>AKT-GLUT1/HKII</td>
</tr>
<tr>
<td>miR-128</td>
<td>suppresses tumourigenesis, angiogenesis and lymphangiogenesis</td>
<td>VEGF-C</td>
</tr>
</tbody>
</table>

---

Li Ke et al.
195, miR-203, miR-221, and miR-222) were correlated with NSCLC. The studies described above clearly suggest that abnormal miRNAs expressions can be used as diagnostic tools in NSCLC. However, due to the differences in methodology and quality control, as well as the limited number of microRNAs and samples studied, existing studies generally lack repeatability. Therefore, better research strategies and more detailed work will be required in the near future.

The prognostic value of miRNAs in NSCLC

Recently, many studies have reported that some miRNAs can be used as prognostic markers in NSCLC. A meta-analysis provided evidence that the high expression of miR-21, miR-200c, and miR-125b was negatively associated with survival in NSCLC patients, while the high expression of miR-148b, miR-365, miR-124, miR-32, miR-146a, and miR-375 was significantly associated with a better prognosis. Wang and his colleagues identified that 11 miRNAs, as well as their target genes and transcription factors, may be profitable in the prognostic prediction of NSCLC as biomarkers. In NSCLC blood samples, Wang et al. found that serum miR-98 expression was down-regulated in patients with NSCLC, and the decreased serum miR-98 was positively correlated with a worse TNM stage, lymph node metastasis, as well as unfavorable overall survival. Guo et al. showed that a decreased miR-204 level in plasma is associated with a poor prognosis in NSCLC patients. Wang and his coworkers revealed that high serum miR-411 expression could serve as a non-invasive prognostic biomarker for NSCLC patients. In NSCLC tissues, Li et al. report that miR-146 is highly expressed in cancer tissues, which can be used to predict the prognosis of NSCLC. Wang et al. reveal that there is an obviously down-regulated miR-148b expression in NSCLC tissues, and the low miR-148b expression is closely related with poor survival of NSCLC patients. Zhang et al. demonstrate that a high expression level of miR-221 is associated with the short overall survival time for NSCLC patients. Cancer-associated fibroblasts (CAFs) play a vital role in promoting tumor progression. Hepatocyte growth factor (HGF) is a protein produced by CAFs that promotes tumor growth, motility, and morphogenesis. The expression of miR-200 A in matrix fibroblasts is negatively correlated with HGF expression. High miR-200a and low HGF expression in stromal fibroblasts may predict a good prognosis in patients with NSCLC. Further, Zhao and his colleagues reported that miRNA single-nucleotide polymorphisms (SNPs) are associated with survival in NSCLC. Their results confirmed that one SNP, rs2042253 is located in the adjacent region of miR-5197-5p, which was associated with improved survival for late-stage NSCLC patients; another SNP, rs7522956, is located in the loop sequences of the miR-4742 gene, and it was significantly associated with the survival of early stage NSCLC patients.

Several recent studies have demonstrated that exosomal miRNAs may serve as prognostic biomarkers for NSCLC. Liu and his coworkers used a qPCR array panel, and found that increased levels of exosomal miR-23b-3p, miR-10b-5p and miR-21-5p were independently associated with a poor overall survival rate for NSCLC. Kanaoka et al. identified high plasma exosomal miR-451a might be a prognostic factor for the overall survival of NSCLC patients. Taken together, these studies show the prognostic value of miRNAs in NSCLC. Nevertheless, to avoid potential biases and limitations, additional validation is still necessary in large patient populations.

MiRNAs for overcoming treatment resistance of NSCLC

Radio- and chemo-resistance hinders success in treating NSCLC. MiRNAs are considered to be resistant against radio- and chemo-therapy in certain types of cancers, including NSCLC.

Radiotherapy

Several studies have identified miRNAs as a predictive biomarker for radiation-resistance in NSCLC. Salim et al. suggested that miRNA-214 could be a putative regulator of radiation-resistance, and miRNA-214 over-expression induced radio-resistance of NSCLC cells. Ma et al. showed that miR-95 was highly expressed in recurrent NSCLC cells, so a decrease could enhance the radio-sensitivity of NSCLC. Yin and his colleagues reported that overexpression of miR-99a increased radio-sensitivity, while inhibition of miR-99a induced radio-resistance of NSCLC cell lines in vitro and in vivo, and the role was at least partially mediated by the mTOR signaling pathway. Furthermore, miR-21 expression is increased in NSCLC; when down-regulated, it can promote NSCLC cell apoptosis induced by irradiation, which indicates that miR-21 may be a potential target for overcoming the radio-resistance of NSCLC. MiR-328-3p is reduced in NSCLC tissues. Up-regulation of miR-328-3p can restore the sensitivity of NSCLC cells to radio therapy, suggesting miR-328-3p may act as a radio-sensitizer for NSCLC therapy. In addition, plasma miRNAs may serve as novel biomarkers for predicting the clinical response of NSCLC radiotherapy. Bioinformatical analysis and clinical verification revealed that four plasma miRNAs (miR-98-5p, miR-302e, miR-495-3p, and miR-613) could be used as radio-sensitivity indicators in patients with NSCLC.
Chemotherapy

Taxanes, including paclitaxel and docetaxel, are the standard treatment for advanced NSCLC. Chen et al. [62] reported that decreased miR-27b expression was associated with docetaxel resistance of NSCLC, while up-regulation of miR-27b could inhibit NSCLC cell viability and enhance the docetaxel sensitivity of NSCLC cells through direct inhibition of EGFR expression. Ye et al. [63] showed that overexpression of miR-186 sensitized NSCLC cells to paclitaxel, whereas inhibition of miR-186 conferred resistance in NSCLC cells. In validation, miR-186 was found to be down-regulated in NSCLC patients who were paclitaxel-resistant, and this decrease was associated with poor survival. Xu et al. [64] revealed a differential expression of miR-30a-5p in two NSCLC cells (paclitaxel-resistant vs paclitaxel-sensitive NSCLC cells). Their results found that up-regulation of miR-30a-5p sensitized NSCLC cells to paclitaxel both in vitro and in vivo through reducing BCL-2 expression, which provided evidence of the potential utility of miR-30a-5p as a biomarker in predicting paclitaxel responsiveness in NSCLC. Gan et al. [65] observed that overexpression of miR-339-5p enhanced the proliferation inhibition ability of Taxol in NSCLC cells, and their in vivo study demonstrated that up-regulation of miR-339-5p could promote the inhibitory function of Taxol on NSCLC growth.

Cisplatin (DDP) is another classic chemotherapy agent used in the treatment of NSCLC. Yuwen et al. [66] identified that serum exosomal miR-146a-5p might be a new biomarker for predicting the efficacy of DDP for NSCLC patients and real-time monitoring drug resistance. Shi et al. [67] also investigated the role of miR-146a in the development of acquired drug resistance to DDP in NSCLC cells, and found that overexpression of miR-146a significantly increased the sensitivity of NSCLC cells to DDP via blocking the cell cycle, enhancing cell apoptosis, and inhibiting cell viability and motility both in vitro and in vivo. Ma et al. [68] reported that DLK1 was a potential target for miR-129-5p, and overexpression of miR-129-5p could inhibit NSCLC chemo-resistance to DDP through regulating DLK1. Li et al. [69] found that miR-196a was associated with the development of NSCLC. Down-regulation of miR-196a may increase the sensitivity of NSCLC cells to DDP by inducing apoptosis in vitro and in vivo. Another study [70] indicated that miR-181c conferred resistance to DDP in NSCLC cells by activating the Wnt/β-catenin pathway through inhibiting WIF1, providing a potential therapeutic target for NSCLC patients with DDP resistance.

In summary, these studies suggest that miRNAs are closely related to the resistance of NSCLC to radiotherapy and chemotherapy, but research into the relationship between miRNAs and therapeutic resistance is still in its infancy. Before applying this theory in clinical practice, studies with larger sample sizes and methods validation procedures will be indispensable.

CONCLUSION

The abnormal expression of miRNAs is closely related to the occurrence and development of NSCLC and regulates the differentiation, proliferation and apoptosis of NSCLC cells, participates in the invasion and metastasis of NSCLC cells, and affects resistance to anti-cancer drugs. Additionally, miRNAs have potential value in the diagnosis, treatment, prognosis and risk stratification of NSCLC. However, the application of miRNAs is mainly based on laboratory research, which lacks large-scale clinical transformation research. Therefore, a more in-depth study of miRNAs may lead to a new method for the diagnosis and treatment of lung cancer.

REFERENCES


Li Ke et al
ternational journal of experimental cellular physiology, biochemistry, and pharmacology 42, 1431-1441


Society for Oncodevelopmental Biology and Medicine


